Global Age-related Macular Degeneration (AMD) Market Projected to Reach $25.40 Billion by 2034, Growing at a CAGR of 8.0%

Market Overview.

Global Age-related Macular Degeneration (AMD) Market size and share is currently valued at USD 11.79 billion in 2024 and is anticipated to generate an estimated revenue of USD 25.40 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 8.00% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034

The global Age-related Macular Degeneration (AMD) market has witnessed notable growth in recent years, driven by the rising prevalence of ocular disorders, increasing aging populations, and advancements in ophthalmic treatments. AMD is a chronic eye condition that primarily affects the macula, leading to progressive vision loss among older adults. The condition has become a significant public health concern, prompting a surge in research, innovative therapies, and diagnostic solutions to manage and slow disease progression.

The AMD market encompasses treatments, diagnostics, and therapeutics designed to manage both wet and dry forms of the disease. Treatments include anti-VEGF therapy, photodynamic therapy, laser surgery, and nutritional supplements, while diagnostics cover imaging technologies and retinal assessment tools. North America and Europe dominate the market due to well-established healthcare infrastructure, early adoption of advanced therapies, and rising awareness of eye health. Asia-Pacific is emerging as a high-growth region, driven by the increasing elderly population, rising healthcare spending, and expanding access to ophthalmic care.

Market segmentation includes disease type, treatment type, end-user (hospitals, clinics, and specialty centers), and geographic regions. Increasing integration of advanced imaging technologies and telemedicine solutions is enhancing early diagnosis and treatment monitoring, improving patient outcomes.

Key Market Growth Drivers

Several factors are fueling growth in the AMD market:

• Rising prevalence of age-related ocular disorders: Aging populations in developed and developing countries drive demand for AMD treatments.

• Technological advancements in therapies: Anti-VEGF injections, gene therapies, and retinal implants are enhancing treatment effectiveness.

• Increasing awareness of eye health: Patient education and preventive care initiatives promote early diagnosis and treatment.

• Expansion of healthcare infrastructure: Development of specialized ophthalmology centers facilitates better access to care.

• Growing research and development: Investment in novel therapies and diagnostic tools fuels innovation and market growth.

Key Market Dynamics

The AMD market is influenced by several critical dynamics:

• Innovation in drug delivery systems: Sustained-release formulations and minimally invasive treatments improve patient adherence.

• Integration of advanced diagnostics: Optical coherence tomography (OCT) and fundus imaging allow early detection and monitoring.

• Strategic collaborations: Partnerships between pharmaceutical companies, research institutes, and hospitals promote new treatment development.

• Government support and reimbursement policies: Favorable healthcare policies enhance access to AMD therapies.

𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

• Acucela Inc.

• Alimera Sciences Inc.

• ALLERGAN

• Bausch & Lomb Incorporated

• Bayer AG

• F. Hoffmann La Roche

• GlaxoSmithKline PLC

• Novartis AG

• Ophthotech Corporation

• Pfizer Inc

• Regeneron Pharmaceuticals

• Rxi Pharmaceuticals Inc.

• Santen Pharmaceuticals Co.

• Valeant Pharmaceuticals International

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/global-age-related-macular-degeneration-amd-market

Market Challenges and Opportunities

While the AMD market is growing, several challenges and opportunities exist:

Challenges:

• High treatment costs: Advanced therapies, such as anti-VEGF injections, may be expensive for patients in certain regions.

• Limited access in developing countries: Lack of specialized ophthalmology centers hinders treatment availability.

• Disease complexity: AMD progression varies among patients, complicating treatment plans.

• Regulatory hurdles: Approval processes for new drugs and therapies can be lengthy and costly.

Opportunities:

• Expansion in emerging markets: Asia-Pacific and Latin America present substantial growth potential due to rising elderly populations.

• Development of novel therapies: Gene therapy, stem cell-based treatments, and next-generation anti-VEGF drugs offer growth avenues.

• Telemedicine adoption: Remote diagnostics and monitoring enhance access to AMD care.

• Preventive and awareness programs: Educational initiatives and early screening can expand the patient base seeking treatment.

Market Trends – Country-wise Analysis

• United States: The U.S. market is driven by early adoption of anti-VEGF therapies, advanced retinal imaging, and strong healthcare infrastructure.

• Canada: Canadian trends focus on patient-centric care, reimbursement for therapies, and access to specialized ophthalmology centers.

• United Kingdom: UK initiatives emphasize early diagnosis, use of advanced diagnostic tools, and integration of AMD care with general ophthalmology services.

• Germany: Germany leads in R&D for novel therapies, advanced imaging systems, and clinical trials for innovative treatments.

• China: Rapid urbanization, aging population, and expanding healthcare infrastructure drive demand for AMD treatments.

• India: Growing awareness, increasing healthcare spending, and the establishment of specialized eye care centers support market growth.

• Japan: Japan emphasizes advanced treatment adoption, gene therapy research, and preventive eye health programs for its aging population.

Future Outlook

The global Age-related Macular Degeneration (AMD) Market is expected to maintain robust growth in the coming years, driven by innovation in therapies, advanced diagnostics, and rising demand for early intervention. Pharmaceutical companies and healthcare providers are likely to focus on cost-effective treatment solutions, accessibility, and patient-centric care to expand their market reach.

Emerging regions, particularly Asia-Pacific and Latin America, present significant opportunities for market growth. By enhancing awareness, expanding specialized ophthalmology services, and introducing affordable treatment options, market players can address the growing burden of AMD. The convergence of innovative therapies, diagnostic advancement